Overview
Liver involvement is one of the major systemic features of Alström Syndrome. Non-alcoholic fatty liver disease (NAFLD) is nearly universal in adults with Alström, and a meaningful proportion progress to fibrosis and cirrhosis. End-stage liver disease accounts for around 10% of deaths in Alström.¹ This article covers what happens to the liver in Alström, how it's monitored, and what helps preserve liver function.
What happens to the liver in Alström
The progression typically follows:
1. Hepatic steatosis (fatty liver) — fat accumulation in liver cells, usually appearing in childhood or adolescence 2. Hepatosplenomegaly — enlarged liver and spleen 3. Steatohepatitis (NASH) — inflammation alongside fat accumulation 4. Fibrosis — scarring of liver tissue 5. Cirrhosis — extensive scarring with loss of liver function in some patients 6. End-stage liver disease — portal hypertension, esophageal varices, hepatic encephalopathy²
Not everyone with Alström progresses to cirrhosis, but the underlying NAFLD is essentially universal in adults.
Why liver disease develops
Several factors contribute:
- Severe insulin resistance — drives fatty liver throughout the body
- Hypertriglyceridemia — adds to hepatic fat load
- Direct ALMS1-related effects on hepatic cells
- Obesity — adds to NAFLD progression
- Diabetes — accelerates liver damage
The combination is more aggressive than typical adult NAFLD in the general population.
Symptoms
Early liver disease in Alström is usually silent. Lab tests detect it before symptoms develop. Late-stage symptoms include:
- Fatigue
- Yellowing of the skin or eyes (jaundice)
- Swelling of the abdomen (ascites)
- Easy bruising or bleeding
- Confusion or mental changes (hepatic encephalopathy)
- Vomiting blood (esophageal varices)
These warrant urgent medical evaluation.
Monitoring
The 2020 international consensus guidelines recommend:³
Annual surveillance
- Liver function tests — AST, ALT, alkaline phosphatase, bilirubin
- Abdominal ultrasound — assesses fatty liver and liver/spleen size
- Coagulation tests — INR
- Albumin and platelet count
- AFP screening for liver cancer in some patients
When changes appear
- FibroScan (transient elastography) — measures liver stiffness, reflecting fibrosis
- MR elastography — more accurate but expensive
- Liver biopsy — definitive but invasive, used in selected cases
- More frequent monitoring of labs and imaging
Advanced disease monitoring
- Endoscopy to look for esophageal varices
- More frequent labs
- Hepatology consultation
Slowing progression
Metabolic management
- Tight diabetes control
- Lipid management (especially triglycerides)
- Weight management within what's achievable
- Blood pressure control
Lifestyle
- Limit alcohol — additional alcohol exposure accelerates liver damage. Many hepatologists recommend abstaining entirely in adults with significant NAFLD
- Mediterranean-style or low-glycemic diet — has the most evidence for benefit in NAFLD
- Regular physical activity — helps liver health independently of weight
- Avoid hepatotoxic medications when possible
Medications
- Vitamin E — limited benefit in some patients with NASH (used selectively)
- Pioglitazone — has evidence for benefit in NASH but considerations for use
- GLP-1 agonists — emerging evidence for liver benefit
- SGLT2 inhibitors — also showing liver benefits in trials
- Specific liver therapies — investigational; not yet routine⁴
Treatment of complications
- Esophageal varices — surveillance, banding, beta-blockers
- Ascites — diuretics, paracentesis, sodium restriction
- Hepatic encephalopathy — lactulose, rifaximin
- Liver cancer screening in patients with cirrhosis
Liver transplant in Alström
For patients who develop end-stage liver disease, transplant is an option. As with heart transplant, decisions are individualized based on overall health and other Alström-related involvement. Combined liver-kidney transplant is considered when both organs are at end-stage.⁵
Coordinating with other care
Liver health interacts with:
- Diabetes management — many medications affect liver
- Heart disease — heart medications are processed by the liver; liver disease affects dosing
- Kidney disease — combined liver-kidney issues complicate care
- Pulmonology — sleep apnea worsens NAFLD
- Surgery — anesthesia and surgical risk increase with liver disease
Common questions
Frequently asked questions
Short answers grounded in the article and the underlying references, so families can quickly understand the main point without losing the medical meaning.
Question
Will my child develop cirrhosis?
Answer
NAFLD is nearly universal in adult Alström, but not everyone progresses to cirrhosis. Many adults have stable steatosis or mild fibrosis throughout life. Annual monitoring catches concerning changes early.
Question
Should we restrict our child's diet to protect the liver?
Answer
Reasonable family-friendly nutrition (lower added sugars, lower refined carbohydrates, Mediterranean-style) helps liver and overall metabolism. Aggressive restriction in young children isn't recommended.
Question
Is alcohol completely off-limits in adult Alström?
Answer
Many hepatologists recommend complete abstinence given the underlying NAFLD. Some allow very moderate alcohol in patients without significant fibrosis. Discuss with your hepatologist.
Question
Are there specific medications to avoid?
Answer
Many medications are processed by the liver. Some that are concerning in significant liver disease include high-dose acetaminophen, some antibiotics, certain anticonvulsants, and some statins (though most statins are now considered safer in NAFLD than previously thought). Discuss any new medication with your team.